Search

A new and effective palladium catalyst supported on a magnesium organosilicate for application in the Heck reaction is presented. A group of compounds comprising 22 examples were synthesized in moderate to high yields (up to 99%) within a short time. The palladium supported on magnesium organosilicate catalyst was characterized as an amorphous solid by SEM, containing around 33% of palladium inside the solid, and even with this low quantity of palladium, the catalyst was very efficient in the Heck reaction. Besides, based on the Scherrer equation, the crystallite size of the synthesized palladium nanoparticles was ultrasmall (around 1.3 nm). This strategy is a simple and efficient route for the formation of C–C bonds via the Heck cross-coupling reaction. [ABSTRACT FROM AUTHOR]

The palladium-catalyzed Suzuki–Miyaura cross-coupling reaction is one of the most important and efficient reactions to prepare a variety of organic compounds, including biaryls. Despite the overwhelming number of reports related to this topic, some methodological difficulties persist in terms of catalyst handling, recovery, and reuse, as well as the reaction media. This work reports the rational design of new, efficient, cost-effective, and reusable palladium catalysts supported on synthetic talc for the Suzuki–Miyaura reaction. From the results, key points were identified: both designed catalysts accelerated the reaction in EtOH and an open-flask setup, affording moderate to excellent yields within a short time (e.g., 30 min) even for deactivated aryl halides; the protocol can be applied to a great number of both cross-coupling partners, showing an excellent functional group tolerance; the catalysts can be recovered and reused without significant loss of activity. This protocol was used for the synthesis of a precursor of angiotensin II inhibitors such as valsartan, losartan, irbesartan, and telmisartan. [ABSTRACT FROM AUTHOR]

Copyright of Synthesis is the property of Georg Thieme Verlag Stuttgart and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

A simple and convenient route for the synthesis of thia‐Michael products was established using pyrazol‐5(4H)‐one with various thiophenols in the presence of [Zn(L‐Pro)2],an efficient catalyst under mild reaction conditions. The salient features of this methodology are good yields, eco‐friendly catalyst, low catalyst loading and faster reaction times. [ABSTRACT FROM AUTHOR]

[Ce(L-Pro)2]2 (Oxa) was used as a recyclable heterogeneous catalyst under mild conditions for the preparation of 2-aryl-2,3-dihydroquinazolin-4(1H)-one derivatives. The one-pot protocol proceeds in ethanol using anthranilamide with several aldehydes at 50-55 °C. The catalyst can be recycled and reused three cycles without significant loss of catalytic activity. [ABSTRACT FROM AUTHOR]

We developed a novel and highly efficient protocol for the synthesis of important pyrazole derivatives by using some 1,3-dicarbonyl compounds and phenyl hydrazines via a one-pot protocol. As a recyclable heterogeneous catalyst, we used [Ce(l-Pro)2]2 (Oxa). In addition, the catalyst is recyclable, the proline is economically viable and readily available in both enantiomeric forms and the catalyst is insoluble in almost all solvents and may be easily filtered off from the reaction medium. Moreover, this new synthetic protocol features high conversion, short reaction times, a straightforward procedure and cleaner reaction profiles. [ABSTRACT FROM AUTHOR]

The efficacy of 5-((4-methoxyphenyl)thio)benzo[c][1,2,5] thiodiazole (MTDZ) in mitigating paclitaxel (PTX)-induced peripheral neuropathy was investigated in male and female Swiss mice. The study examined the effects of MTDZ on various pathways, including transient receptor potential cation channel subfamily V member 1 (TRPV1), glutamatergic, nitrergic, guanylate cyclase (cGMP), serotonergic, and opioidergic. Mice received intraperitoneal PTX (2 mg/kg) or vehicle on days 1, 2, and 3, followed by oral MTDZ (1 mg/kg) or vehicle from days 3 to 14. Mechanical and thermal sensitivities were assessed using Von Frey and hot plate tests on days 8, 11, and 14. The open field test evaluated locomotion and exploration on day 12. On day 15, nitrite and nitrate (NOx) levels and Ca 2+ -ATPase activity in the cerebral cortex and spinal cord were measured after euthanizing the animals. MTDZ administration reversed the heightened mechanical and thermal sensitivities induced by PTX in male and female mice without affecting locomotion or exploration. MTDZ also modulated multiple pathways, including glutamatergic, NO/L-arginine/cGMP, serotonergic (5-HT 1A/1B ), opioid, and TRPV1 pathways. Additionally, MTDZ reduced NOx levels and modulated Ca 2+ -ATPase activity. In conclusion, MTDZ effectively alleviated PTX-induced peripheral neuropathy and demonstrated multi-targeted modulation of pain-related pathways. Its ability to modulate multiple pathways, reduce NOx levels, and modulate Ca 2+ -ATPase activity makes it a potential pharmacological candidate for peripheral neuropathy, acute nociceptive, and inflammatory conditions. Further research is needed to explore its therapeutic potential in these areas.